EUVIMEDEUVIMED entdecken
Crossref

Disease Course of Eosinophilic Esophagitis Under Anti-inflammatory Treatment

Alain M Schoepfer, Sofia Asikainen, Catherine Saner, Jean-Benoit Rossel, Fritz Murray, Luc Biedermann, Anne Godat, Fabian Luca Meichtry, Alex Straumann, Thomas Greuter, Swiss EoE Cohort Study Group

The Journal of Allergy and Clinical Immunology: In Practice · 2026-08 · 14 (8) · 1791-1798.e4

DOI: 10.1016/j.jaip.2026.03.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-08. Verfasst von Alain M Schoepfer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University Hospital Lausanne-CHUV, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Micropalaeontological Society, Sanofi, Dr. Falk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic type 2 inflammatory disease of the esophagus that progresses to a fibrotic phenotype when left untreated. Current treatment options aim to control clinical, endoscopic, and histological disease activity. However, as of yet, it remains elusive if achieving disease control, particularly the long-term control of histological disease activity, can prevent the development of disease complications. OBJECTIVE: We aimed to assess the impact of ongoing histological disease activity on the development of disease complications in adult patients with EoE. METHODS: We evaluated prospectively included patients in the Swiss EoE cohort. Data on all patients with ongoing maintenance treatment, and at least 2 follow-up visits, but without concomitant gastroesophageal reflux or strictures at baseline, were analyzed. We compared patients with ongoing histological disease activity versus patients with disease control, with regard to development of disease complications over time (strictures, bolus impactions, and need for treatment escalation). Histological disease activity was defined by a peak eosinophil count of ≥15 eosinophils during all follow-up visits. RESULTS: We included a total of 151 patients with a median follow-up of 56.0 months (70.9% male, median age 39.0 years). A total of 93 patients (61.6%) were classified as having disease control during follow-up, whereas 58 patients (38.4%) showed ongoing histological disease activity. Development of complications occurred in a total of 108 patients (71.5%), significantly more often in patients with ongoing histological activity compared with patients with disease control (89.7% vs 60.2%, P < .001). This difference was mainly due to higher rates of stricture formation and the need for treatment escalation. Multivariate Cox regression models revealed ongoing histologic disease activity as a significant predictor of the development of complications in the follow-up (hazard ratio [HR]: 2.45, P < .001), particularly for the need for treatment escalation (HR: 2.63, P < .001) and development of strictures (HR: 3.16, P = .025). CONCLUSIONS: Ongoing histological disease activity predicts development of complicating disease course in patients with EoE. Current treatment strategies should aim to control both clinical and histological disease activity to prevent disease complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAnti-Inflammatory AgentsHumansFemaleMaleAdultDisease ProgressionEosinophilsMiddle AgedProspective StudiesFollow-Up StudiesSwitzerlandEsophagus

Stichwörter der Autor:innen

Anti-inflammatory treatmentComplicationsEosinophilic esophagitisEosinophilsHistologic disease activity

Substanzen

Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University Hospital Lausanne-CHUV, Lausanne, Switzerland.
  • Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland; Division of Gastroenterology and Hepatology, EOC Lugano, Lugano, Switzerland.
  • Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Division of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Division of Gastroenterology and Hepatology, University Hospital Lausanne-CHUV, Lausanne, Switzerland; Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Zurich, Switzerl…

Förderung

  • Micropalaeontological Society
  • Sanofi
  • Dr. Falk Pharma
  • Novartis Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Schoepfer, A. M., Asikainen, S., Saner, C., Rossel, J. B., Murray, F., Biedermann, L., Godat, A., Meichtry, F. L., Straumann, A., Greuter, T., & Swiss EoE Cohort Study Group (2026). Disease Course of Eosinophilic Esophagitis Under Anti-inflammatory Treatment. The Journal of Allergy and Clinical Immunology: In Practice, 14(8), 1791-1798.e4. https://doi.org/10.1016/j.jaip.2026.03.014

Vancouver

Schoepfer AM, Asikainen S, Saner C, Rossel JB, Murray F, Biedermann L, et al. Disease Course of Eosinophilic Esophagitis Under Anti-inflammatory Treatment. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(8):1791-1798.e4. doi:10.1016/j.jaip.2026.03.014

BibTeX
@article{Schoepfer2026,
  author = {Schoepfer, Alain M and Asikainen, Sofia and Saner, Catherine and Rossel, Jean-Benoit and Murray, Fritz and Biedermann, Luc and Godat, Anne and Meichtry, Fabian Luca and Straumann, Alex and Greuter, Thomas and Swiss EoE Cohort Study Group, Swiss EoE Cohort Study Group},
  title = {Disease Course of Eosinophilic Esophagitis Under Anti-inflammatory Treatment},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {1791--1798.e4},
  doi = {10.1016/j.jaip.2026.03.014}
}
Kostenlos starten →